ClinicalTrials.gov
ClinicalTrials.gov Menu

Impact of Screening Patients With HIV for Kidney Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00392132
Recruitment Status : Withdrawn (Sufficient study funding was not obtained.)
First Posted : October 25, 2006
Last Update Posted : November 26, 2008
Sponsor:
Information provided by:
University of Mississippi Medical Center

Study Description
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The Infectious Disease Society of America has recently recommended that patients with Human Immunodeficiency Virus (HIV) be screened for kidney disease on a regular basis. Screening involves non-invasive urine and blood test and a screening program has already been initiated here in the University of Mississippi HIV clinic. This study looks at the effect of this new screening program. Our Hypothesis is that screening for kidney disease is a cost effective and important addition to the care of patients with HIV.

Condition or disease
HIV Infections Renal Insufficiency, Chronic Proteinuria

Detailed Description:

The Infectious Disease Society of America has recently recommended that patients with Human Immunodeficiency Virus (HIV) be screened for kidney disease on a regular basis. Screening involves non-invasive urine and blood test and a screening program has already been initiated here in the University of Mississippi HIV clinic. However nobody knows for sure whether this will help doctors take better care of patient with HIV.

This study looks at the effect of this new screening program. We want to see how frequently abnormalities are seen on screening, how frequently certain kidney diseases are diagnosed, how often patients are referred to a nephrologist and how often a patient's management is changed by the screening. We will also estimate the cost-benefit ratio of the screening. We will review patient charts to determine what has happened in each case where screening was conducted.

This study will not involve any additional testing.

The benefit of this study will be improving our understanding of kidney disease in HIV. It will help us determine the value of screening for kidney disease and the frequency of certain kidney diseases in HIV in our clinic population.


Study Design
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Observational
Enrollment : 1400 participants
Official Title: Impact of Screening Patients With HIV for Kidney Disease
Study Start Date : October 2005
Estimated Primary Completion Date : October 2006
Estimated Study Completion Date : October 2006

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Eligibility Criteria
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult patients with HIV who are seen by the University of Mississippi Infectious disease clinic at the Jackson Medical Mall or patient seen at the University of Mississippi Nephrology Clinic.
Contacts and Locations
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00392132


Locations
United States, Mississippi
University of Mississippi Medical Center
Jackson, Mississippi, United States, 39216-4505
Sponsors and Collaborators
University of Mississippi Medical Center
Investigators
Principal Investigator: Darren W Schmidt, MD University of Mississippi Medical Center
More Information
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party: Darren Schmidt, Assistant Professor of Medicine, University of Mississippi Medical Center
ClinicalTrials.gov Identifier: NCT00392132     History of Changes
Other Study ID Numbers: UMMC - HIV and CKD
First Posted: October 25, 2006    Key Record Dates
Last Update Posted: November 26, 2008
Last Verified: November 2008

Keywords provided by University of Mississippi Medical Center:
HIV

Additional relevant MeSH terms:
HIV Infections
Kidney Diseases
Renal Insufficiency
Proteinuria
Renal Insufficiency, Chronic
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
 Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Urologic Diseases
Urination Disorders
Urological Manifestations
Signs and Symptoms